Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Income (2016 - 2025)

Historic Net Income for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Net Income rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
  • Per Theravance Biopharma's latest filing, its Net Income stood at $3.6 million for Q3 2025, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Income ranged from a high of $927.1 million in Q3 2022 and a low of -$23.1 million during Q4 2024
  • For the 5-year period, Theravance Biopharma's Net Income averaged around $50.3 million, with its median value being $3.6 million (2025).
  • Per our database at Business Quant, Theravance Biopharma's Net Income surged by 440000.49% in 2022 and then plummeted by 31854.13% in 2023.
  • Theravance Biopharma's Net Income (Quarter) stood at $25.8 million in 2021, then plummeted by 84.9% to $3.9 million in 2022, then plummeted by 318.54% to -$8.5 million in 2023, then crashed by 171.45% to -$23.1 million in 2024, then surged by 115.65% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.5 million during Q1 2025.